Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mark A. Matson"'
Autor:
Mark A. Matson, Eran Schenker, Michal Stein, Vladislava Zamfirova, Huy-Binh Nguyen, Garrett E. Bergman
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 2, Pp 452-459 (2020)
We conducted a clinical trial to assess the safety and putative efficacy of an additional human rabies immune globulin (HRIG; KEDRAB) versus an older product (Comparator, HyperRAB S/D® [Grifols]) and determine whether HRIG interferes with developmen
Externí odkaz:
https://doaj.org/article/63b95ec0e2d24d4d9794f89fbd9c4ace
Autor:
Shivang Bhakta, Devang K. Sanghavi, Patrick W. Johnson, Katie L. Kunze, Matthew R. Neville, Hani M. Wadei, Wendelyn Bosch, Rickey E. Carter, Sadia Z. Shah, Benjamin D. Pollock, Sven P. Oman, Leigh Speicher, Jason Siegel, Claudia R. Libertin, Mark W. Matson, Pablo Moreno Franco, Jennifer B. Cowart
Publikováno v:
International Journal of Infectious Diseases, Vol 120, Iss , Pp 88-95 (2022)
Objectives: The emergence of SARS-CoV-2 variants of concern has led to significant phenotypical changes in transmissibility, virulence, and public health measures. Our study used clinical data to compare characteristics between a Delta variant wave a
Externí odkaz:
https://doaj.org/article/4c1292b005c54af0946b46775b040e68
Autor:
Mark A Matson
Publikováno v:
The Journal of Theological Studies. 73:308-310
Low antispike antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations
Autor:
Devang K. Sanghavi, Shivang Bhakta, Hani M. Wadei, Wendelyn Bosch, Jennifer B. Cowart, Rickey E. Carter, Sadia Z. Shah, Benjamin D. Pollock, Matthew R. Neville, Sven P. Oman, Leigh Speicher, Jason Siegel, Ameya D. Scindia, Claudia R. Libertin, Katie L. Kunze, Patrick W. Johnson, Mark W. Matson, Pablo Moreno Franco
Publikováno v:
Journal of internal medicine. 292(1)
While COVID-19 immunization programs attempted to reach targeted rates, cases rose significantly since the emergence of the delta variant. This retrospective cohort study describes the correlation between antispike antibodies and outcomes of hospital
Autor:
Sadia Z. Shah, Shivang Bhakta, Sven P. Oman, Hani M. Wadei, Mark W Matson, Pablo Moreno Franco, Devang Sanghavi, Benjamin D. Pollock, Jennifer B Cowart, Ameya D Scindia, Rickey E. Carter, Wendelyn Bosch, Leigh L. Speicher, Matthew R. Neville
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
We characterized coronavirus disease 2019 (COVID-19) breakthrough cases admitted to a single center in Florida. With the emergence of delta variant, an increased number of hospitalizations was seen due to breakthrough infections. These patients were
Autor:
Mark A. Matson, Eran Schenker, Huy-Binh Nguyen, Michal Stein, Garrett E. Bergman, Vladislava Zamfirova
Publikováno v:
Human Vaccines & Immunotherapeutics
We conducted a clinical trial to assess the safety and putative efficacy of an additional human rabies immune globulin (HRIG; KEDRAB) versus an older product (Comparator, HyperRAB S/D® [Grifols]) and determine whether HRIG interferes with developmen
Autor:
Steven M. Leonardo, Ross B. Fulton, Kathryn A. Fraser, Mark T. Uhlik, Xiaohong Qiu, Jamie Lowe, Mark A. Matson, Keith B. Gorden, Lindsay R Jordan, Nadine R. Ottoson, Nandita Bose, Blaine Rathmann, Adria Jonas, Richard Walsh, Takashi O Kangas, Ben Harrison, Anissa S.H. Chan, Kathleen E. Ertelt, Jeremy R. Graff, Richard D. Huhn
Publikováno v:
The Journal of Immunology. 202:2945-2956
Imprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (AB
Autor:
Betsy T. Kren, Mark A. Matson, Katherine W. Zerebiec, Jay C. Zeller, Hugh McTavish, Laurie L. Shekels
Publikováno v:
Immunity, Inflammation and Disease
Introduction Differences in immune characteristics, including immune gene expression by peripheral blood mononuclear cells (PBMCs), correlating with herpes labialis and good or poor immune control of herpes simplex virus type 1 (HSV‐1), and how the
Autor:
Xiaoyan Li, Charles M Psoinos, Mark Joel Shelton, Farida Abane, Mark A. Matson, Samuel Oberstein, Rodrigo Ruiz-Soto
Publikováno v:
Journal of Clinical Oncology. 40:e16031-e16031
e16031 Background: Ripretinib is a tyrosine kinase inhibitor indicated for the treatment of patients with advanced gastrointestinal stromal tumor who have received prior treatment with ≥3 kinase inhibitors, including imatinib. Ripretinib and its ac
Autor:
Mark A. Matson
Publikováno v:
The Journal of Theological Studies. 68:286-288